Android app on Google Play

Alnylam Pharmaceuticals (ALNY) Slumps as Researchers Raise Red Flags

March 21, 2013 2:39 PM EDT Send to a Friend
Shares of Alnylam Pharmaceuticals (Nasdaq: ALNY) slumped on Thursday. Traders say the stock's decline could relate to questions raised about treatments targeting alpha-synuclein. According to reports, drugs aimed at alpha-synuclein could be making people worse. Questions raise concerns about patients in clinical trials to lower alpha-synuclein.

You May Also Be Interested In

Related Categories

FDA, Rumors, Trader Talk

Add Your Comment